Americans should be concerned about the amount of fluoride they consume. It is not found only in drinking water; fluoride exposure can also come from toothpaste, mouthwash, certain pharmaceuticals, professionally applied dental treatments, and other everyday sources. Yet most discussions of fluoride tend to examine these sources individually rather than asking a broader question: What is the cumulative effect of repeated exposure from multiple sources over decades of a person’s life?
To decide for yourself what level of fluoride exposure you consider appropriate, it is first necessary to understand how fluoride became so deeply embedded in modern public health and dental practice. That story—shaped by scientific discovery, industrial development, government policy, dentistry, medicine, and decades of controversy—is the subject of this paper.
For decades, Americans have been given a remarkably simple explanation of water fluoridation. It appears to me to be one of the earliest examples of supplementing the American experience with helpful naturally occurring elements.
In 1995, the Centers for Disease Control and Prevention described it this way:
“Water fluoridation is the deliberate addition of the natural trace element fluorine (in the ionic form as fluoride) into drinking water in accordance with scientific and dental guidelines.”
Read that sentence carefully.
It creates a reassuring picture: fluoride exists naturally in water; some communities don’t have enough; therefore water utilities simply adjust the amount of this naturally occurring substance to a level believed to prevent cavities.
That description isn’t entirely false. But is the fluoride we are adding to our water supply the same naturally occurring trace element that was given credit in the early 1900s for improving dental health?
A brief review of the industrial history shows that is not the case.
The fluoride compounds most commonly used today to fluoridate American drinking water do not come from collecting naturally fluoridated water or grinding up naturally occurring calcium fluoride. Much of the fluorosilicic acid used by American water systems is produced in connection with the manufacture of phosphate fertilizer.
The Environmental Protection Agency describes the process plainly. Phosphate rock contains fluorine. When that rock is processed with sulfuric acid to manufacture phosphoric acid for fertilizer, fluoride-containing gases — including hydrogen fluoride (HF) and silicon tetrafluoride (SiF₄) — are released.
Those gases cannot simply be discharged into the atmosphere. They are captured in wet scrubbers. When they are scrubbed with water, something useful — and problematic — happens.
The EPA’s 2022 Fluorosilicic Acid (FSA) Supply Chain Profile states:
“When the gases are scrubbed with water, FSA is formed as a waste stream.”
Today its primary commercial use is water fluoridation. CDC data indicate that water systems deliberately adjusting fluoride levels, together with systems purchasing that treated water, serve more than 200 million people — nearly six in ten Americans.
How did we get from observing fluoride in groundwater to adding an industrially recovered material to drinking water serving more than half the country?
The Original Fluoride Discovery
The scientific story began with a legitimate observation.
During the early twentieth century, dentists noticed that people in certain communities developed mottled or stained teeth — what became known as dental fluorosis.
The trail started in Colorado Springs. In 1901 a young dentist named Frederick McKay arrived there and found that many of his patients had permanently brown-stained enamel. With G.V. Black he spent years showing the stain tracked the local water, not hygiene or diet. He still did not know what was in the water.
That answer came in 1931. H. V. Churchill, a chemist at Alcoa’s plant in Bauxite, Arkansas, ran spectrographic tests on water from a stained-teeth town and found high fluoride. Independently, H. V. and Margaret Smith at the University of Arizona reached the same conclusion on water from St. David, Arizona. The mottled communities had naturally elevated fluoride in their drinking water.
Then came another observation: populations with some of that naturally occurring fluoride also appeared to have fewer cavities.
Trendley Dean and other researchers at the U.S. Public Health Service mapped that relationship through the 1930s and early 1940s — how much fluoride in the water, how much stain, how much decay. Eventually public-health officials proposed an experiment: if naturally occurring fluoride was associated with fewer cavities, could adding fluoride to low-fluoride water reproduce the apparent dental benefit?
Grand Rapids, Michigan, became the first major American test. On January 25, 1945, Grand Rapids began artificially fluoridating its municipal water with sodium fluoride, a simple salt: one sodium ion and one fluoride ion.
The experiment was originally intended to continue for roughly a decade or longer while researchers compared dental outcomes with those in an unfluoridated control community. The results at five years were positive. In 1950 — only five years after Grand Rapids began — the U.S. Public Health Service endorsed community water fluoridation.
About the same time, another American industry was confronting an entirely different fluoride problem.
The Fertilizer Industry Had a Fluoride Problem
Phosphate fertilizer is older than water fluoridation by a century.
In 1842 John Bennett Lawes patented superphosphate: bones treated with sulfuric acid so plants could use the phosphorus. By 1843 he was making it in England. American works followed in Baltimore and Philadelphia. The feedstock was still bones.
That changed when the rock was found. South Carolina began mining phosphate rock in 1868. In 1881 Francis LeBaron, surveying Florida’s Peace River for the Army Corps, found pebble phosphate in the riverbed. Commercial Florida production followed in 1887–88. Hard-rock and land-pebble mining opened the central Florida field that came to be called the Bone Valley — so named because the draglines kept turning up fossils. From about 1905 Florida land-pebble was the dominant American source.
Phosphate rock is not clean calcium phosphate. It is fluorapatite: calcium, phosphate, and fluorine locked in the same mineral, with silica mixed in. Treat that rock with sulfuric acid — the wet process — and you get phosphoric acid for fertilizer. You also drive off fluorine as hydrogen fluoride and silicon tetrafluoride.
A 1937 patent on recovering values from phosphate rock already described the aim as taking most of the fluorine out of the rock “as a useful marketable compound.”
After World War II the industry stopped shipping most of the rock north and built the acid plants next to the mines. Output soared. Every extra ton of wet-process acid meant more of those gases leaving the reactor.
The gases were not theoretical. On the ground in central Florida it was not ordinary.
After Armour opened a chemical fertilizer and sulfuric-acid plant in 1948, more than a dozen processing works followed in Polk and Hillsborough Counties. By the early 1950s ranchers were reporting herds that would not fatten. Legs deformed. Teeth wore away or fell out. Calves were stillborn. Veterinarians diagnosed fluoride poisoning from forage dusted by plant stacks. Citrus leaves bleached. Gladiolus crops failed. Later accounts of those years put the damage at roughly 150,000 acres of cattle land abandoned and 25,000 acres of citrus harmed.
The plants had to catch what they had been putting up the stack. The engineering answer was wet scrubbing. Pass the gases through water. The fluoride leaves the air and enters a liquid. The harm did not vanish because it changed phase. The scrubber liquor is fluorosilicic acid.
In 1950 Frank J. McClure of the Public Health Service compared sodium fluoride with sodium fluosilicate and concluded the fluorine was available and that the salt could be considered as a substitute. That is a substitution paper. It is not a decade-long trial of hydrofluosilicic acid in a city water supply.
By 1951 the Public Health Service was discussing three principal fluoridation chemicals: sodium fluoride, sodium silicofluoride, and hydrofluosilicic acid. Cost and handling were part of the discussion. Sodium fluoride was the chemical in Grand Rapids. What had been shown about the other two was thinner.
In 1952 a federal survey counted 137 systems on sodium fluoride, 104 on sodium silicofluoride, and 26 already on hydrofluosilicic acid.
A 1955 patent on treating phosphate rock, filed in July 1953, states that at a number of American superphosphate plants the volatilized fluorine was recovered as hydrofluosilicic acid “and is marketed chiefly as barium, zinc, ammonium, magnesium and sodium fluosilicates, principally the latter.”
A patent filed in 1954, later issued as “Disposal of fluorine wastes,” described the fumes from a phosphate-fertilizer plant as something that had to be converted into a form that could be “economically and safely disposed of.”
In 1955, W. L. Hill and K. D. Jacob, writing for the mining profession, treated recovery of fluorine from wet-process plants as ordinary industrial practice. That same year the American Water Works Association — a trade group of utility men founded in St. Louis in 1881 — issued a formal standard for fluosilicic acid used in water treatment.
Ten years after Grand Rapids started with a bag of sodium fluoride, the liquid from the phosphate plant had a specification. Municipal drinking water.
A 1961 paper in the Journal of the Air Pollution Control Association estimated gaseous fluoride from the Florida belt at as much as eight tons a day.
Eventually, the Byproduct Won
Over subsequent decades, fluorosilicic compounds became dominant in American water fluoridation.
EPA researchers reported that by 1992, fluorosilicic acid supplied systems serving approximately 62.6 percent of the artificially fluoridated population. Sodium fluorosilicate accounted for another 28.2 percent. Sodium fluoride — the chemical used in Grand Rapids — accounted for only about 9.2 percent.
That means that by the early 1990s, roughly nine out of ten Americans receiving artificially fluoridated municipal water were served by systems using fluorosilicate chemicals rather than sodium fluoride.
That makes the CDC description worth reading again:
“Water fluoridation is the deliberate addition of the natural trace element fluorine (in the ionic form as fluoride) into drinking water…”
Chemically, the CDC is describing the fluoride ion that exists in the finished water. Industrially, that sentence tells almost none of the story. The material being delivered to many water-treatment facilities is fluorosilicic acid produced through phosphate processing.
Both statements can technically be true. They leave dramatically different impressions.
“Once It’s in the Water, It’s All the Same”
Public-health authorities argue that it ultimately doesn’t matter where the fluoridation chemical originated. Fluorosilicic acid dissociates and hydrolyzes when sufficiently diluted in drinking water. Therefore, according to the conventional explanation, the resulting fluoride is effectively indistinguishable from fluoride that was naturally present.
That sounds reassuring. A pretty straightforward question: where is the human experiment demonstrating that?
The chemistry has been examined for decades. One influential review was written in 2002 by EPA chemist Edward T. Urbansky: Fate of Fluorosilicate Drinking Water Additives. Urbansky reviewed equilibrium chemistry and concluded that under ordinary drinking-water conditions essentially no intact hexafluorosilicate should remain at equilibrium.
A chemical-equilibrium calculation is not the same thing as a lifetime biological experiment. The question I wanted answered is different:
Does the human body handle fluoride derived from fluorosilicic acid the same way it handles fluoride naturally present in water?
There have been human experiments on part of that question. They are small.
Twenty People, Eight Hours
In 2005, A. Maguire and colleagues at Newcastle University published a study the UK Department of Health had commissioned. Twenty healthy adults, ages about 20 to 35, each drank 500 milliliters of water. Some of the water was naturally fluoridated. Some had fluoride added. A line went into a vein. One blood sample before the drink, then eleven more over the next eight hours. The plasma peak they reported came at about fifty minutes.
They did not find a statistically significant difference by source.
That is real data. It is also twenty young adults and one glass. An eight-hour curve can catch the rise in blood and the first decline. In a healthy adult, a large share of an absorbed dose is already moving into bone.
The National Academies, 2006
In 2006, the National Research Council of the National Academies published Fluoride in Drinking Water: A Scientific Review of EPA’s Standards. The committee was not asked to decide whether community water fluoridation at approximately 1 mg/L should continue. It was evaluating EPA’s drinking-water standards, particularly the maximum contaminant level of 4 mg/L.
Its examination of fluoride biology was extensive. The committee reviewed neurological effects, endocrine function, bones, kidneys, reproduction, cancer, fluoride metabolism, susceptible populations, and total exposure. It identified unanswered questions. It called for additional research, over and over. That was 2006. Twenty years ago.
Which leads to the question that started this: what have we learned, what are we doing, what has changed?
Ten People, Six Hours
In 2008, Gary Whitford and colleagues published a second study. Ten healthy adults, ages 24 to 32, drank 500 milliliters containing fluoride that was natural, or added as sodium fluoride, or added as fluorosilicic acid. Blood before the drink, then nine more draws over six hours. Plasma only.
Again, no significant difference in the main measurements.
Ten people. Six hours. One drink.
Neither study was built for pregnancy, old age, bad kidneys, a developing brain, thyroid, bone over decades, cancer, or the pile-up from water plus food plus toothpaste plus medicine. They measured the first hours in blood after a single glass. That is all they can carry.
The Question Isn’t Whether Fluoride Prevents Cavities
The cavity question has owned this fight for decades. It is not the only question, and it may not be the one that matters most now.
Suppose naturally occurring fluoride reduces decay. That still does not settle whether putting a biologically active chemical into everyone’s tap is the way to deliver it. A 200-pound adult drinking a liter does not receive the same dose, per pound, as a 25-pound child drinking the same water. A person with working kidneys is not the same as a person whose kidneys are already tired. Water is not the only source anymore. There is tea, processed food and drinks made with city water, toothpaste, pharmaceuticals. These are not all the same compound. They still add up in one body.
The ten healthy adults and the six-hour blood curve do not answer what happens if a child drinks chemically infused water from infancy to old age. That would take different work: years, not hours; children and sick people, not only students; total intake, not one glass.
I started this thinking I would find a simple dental story. I found mottled teeth in Colorado, a chemist in Arkansas, Grand Rapids and a bag of sodium fluoride, then a fertilizer belt that had to catch its own stack gases, cattle downwind of those plants, and a liquid from the scrubber that became the usual chemical in American tap water. None of that, by itself, proves the finished glass is harming you. It does mean the public story — “we are only topping up a natural mineral” — left a lot out.
The question I cannot get away from is simpler than the cavity debate.
What does this chemical do in a human body, day after day, in the amounts we actually drink?
Until that is answered for the people who actually drink the water — not only for twenty adults on a single morning — we are the experiment.
Your town is not every town.
Fluoride in the tap is not one national phone number or web page. Some cities add it. Some never did. Some have naturally occurring fluoride in the groundwater and add nothing. Some don’t. The concentration on the Consumer Confidence Report — the water-quality report your utility has to publish every year — is the place to start. It will show a fluoride number. Read the notes. Utilities often say the source is “natural deposits” and “a water additive.” That additive, in most of the systems that adjust the level, is hydrofluorosilicic acid. If the report is vague, call the plant and ask what they feed and what the finished water tests.
CDC’s fluoridation pages list which systems adjust. State health departments keep the same lists. Two houses in two counties in the same state can be on different water.
You do not need a federal committee to look at your own glass. You do need the report.
Agencies can take decades to reopen and explore the safety of a chemical that is already in the pipes. A person does not have decades. The history is more complicated than we were told. The small blood studies are not a lifetime. The open questions from 2006 are still open questions.
In the meantime, we are on our own. That means reading the water report, adding up the other sources in the house, testing our own bodies, eliminating the chemicals and quiting to wait for someone else to figure out what a safe amount of a toxic chemical looks like to your body.
M. Whitford et al., “Pharmacokinetics of ingested fluoride: lack of effect of chemical compound,” Arch. Oral Biol.53(11):1037–1041 (2008) https://pubmed.ncbi.nlm.nih.gov/18514162/
When a doctor prescribes a medication, how much do we really know about why it’s being used for our condition? How effective it is? How it was approved, and what it’s supposed to do? Does it help my condition? Is it off-label and exactly what does that mean?
A couple of years ago, I found myself in a hospital room with a brand-new diagnosis: a “rare disease”—an inoperable, incurable brain cancer (primary central nervous system lymphoma, or PCNSL). This was not how I pictured my later years. From the moment I arrived at Mayo Clinic, I knew my issues were tied to my teeth—a systemic dental infection fueling inflammation throughout my cranium. I eventually found my path to wholeness, but along the way, I learned things I wish I’d known sooner. If this resonates, maybe it’ll help you too.
I’ve covered key pieces of this puzzle in previous articles on my site (jjunr.com):
How the government established the framework to support this rare disease (e.g., Orphan Drug Act and beyond) read: From Temporary Fix to Permanent System
And in The Night I Saw Pharma’s Names on My Cancer Protocol, I tie it all together—revealing the interconnectedness of the industry (standard protocols and their connections with pharma-driven solution) versus the patient’s lived reality, choices, and potential for root-cause healing outside the system.
This piece focuses on the medications themselves—how the industry evolved, and what it means for anyone caught in it. ...
What Is Off-Label Use?
Off-label use means a doctor prescribes an FDA-approved drug for a purpose, dose, or patient group not on the official label.
It’s legal and common in the US (10-20% of prescriptions overall, often higher in oncology). Doctors have this flexibility because the FDA regulates drug approval and manufacturer promotion—not how physicians practice medicine.
This has been allowed since the early FDA laws (1906 Pure Food and Drugs Act, strengthened in 1938 and 1962), which separate drug regulation from medical practice.
Many off-label uses become standard through evidence and experience and are not inherently experimental or risky.
Brief History of Off-Label Drug Use
1906: Pure Food and Drugs Act — Required honest labeling; preserved physician freedom.
1938: Federal Food, Drug, and Cosmetic Act — Proof of safety required; affirmed FDA doesn’t control medicine.
1962: Kefauver-Harris Amendments — Proof of efficacy via trials; labels became specific, defining “off-label.”
1983: Orphan Drug Act — Incentives for rare diseases (<200,000 patients); led to approvals but also loopholes like “salami slicing” subsets for exclusivity and high prices.
1990s–Present: Limited off-label info dissemination allowed; ~20% prescriptions off-label, especially in cancer—scrutiny over promotion and costs.
How Does This Translate to the Individual?
Doctors aren’t required to get special written consent for off-label use (beyond general admission consents). It’s up to you to know this and advocate for yourself. Let me share one drug experience that sent me down the rabbit hole. Rituximab was my wake-up call, but the same questions apply to any mediation you are prescribed.
I received two infusions of rituximab (Rituxan/Ruxience). The first was terrifying—I genuinely felt like I was dying. I experienced violent reactions: uncontrollable shivers–my body was in shock. The team reacted quickly, injecting me with the required medications to bring the initial reaction under control, followed by Demerol, I assume to calm me down.
And then they left. As I lay there heavily drugged and recovering, I suddenly realized I had stopped breathing automatically. I had to consciously think “breathe now” just to stay alive. I began flailing my arms and legs desperately—for what felt like hours—waiting for the symptoms to dissipate. It was horrifying.
The team had managed the initial violent reaction but completely missed my frantic efforts to keep myself breathing and conscious in the aftermath. When I later told the doctor about the experience—specifically how I had to deliberately think to breathe—my description was dismissed as an overreaction. But was it really? The black box warning for rituximab, which highlights the risk of serious, including fatal, infusion-related reactions (often involving hypoxia or respiratory issues), would suggest I was fortunate to have survived what could have been deadly.
Recently, when I looked up the drug on the NIH DailyMed page, the black box warning hit me hard: I could easily have died from that infusion
WARNING: FATAL INFUSION-RELATED REACTIONS. – Administration of rituximab products can result in serious, including fatal, infusion-related reactions. Deaths within 24 hours of rituximab infusion have occurred. Approximately 80% of fatal infusion-related reactions occurred in association with the first infusion. Monitor patients closely. Discontinue RUXIENCE infusion for severe reactions…
Section 5.1 goes on to detail: Reactions include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary issues, shock, anaphylaxis, or death—often in the first 30–120 minutes. Premedicate with antihistamine, acetaminophen; for some indications, steroids like methylprednisolone. Manage with epinephrine, oxygen, etc. Reduce rate or stop if severe.
They give multiple drugs just to safely administer this one. And for my case? Zero evidence it helped my variation of PCNSL.
The hospital charged high amounts for these drugs: On December 7, 2023, the rituximab-pvvr (RUXIENCE) injections totaled $11,455. Two weeks later, on December 21, the biosimilar rituximab-abbs rose to $14,063—a roughly 23% increase. Strange how the “cheaper” biosimilar option wasn’t cheaper. Biosimilars are marketed as cost-savers through competition, but in practice (with hospital markups, list prices, or other factors), they don’t always deliver the expected savings to patients or systems—especially in off-label use.
The Clinical Studies Behind the Approval
The DailyMed label for RUXIENCE cites studies from the original Rituxan (not new ones for the biosimilar). These are from Genentech/Roche and Biogen (original developers/marketers), often with academic/cooperative groups (e.g., ECOG, German study groups).
They focus on:
Relapsed/refractory low-grade/follicular NHL (single-agent rituximab).
Adding rituximab to chemo (CVP or CHOP) for untreated follicular or diffuse large B-cell NHL.
CLL with fludarabine/cyclophosphamide.
No large trials for PCNSL appear in the—efficacy data bridges from those original pharma-sponsored studies showing benefits like better response rates and survival in systemic NHL/CLL.
Pfizer (RUXIENCE maker) did smaller biosimilarity trials to prove it’s similar to Rituxan, but the core approval relies on Roche/Biogen’s foundational work. (Truxima/rituximab-abbs has its own separate label, but draws from similar foundational data.)
Profit Ties: Roche/Biogen profit from branded Rituxan (billions historically). Pfizer (and others like Teva for Truxima) profit from biosimilar versions, capturing market share. The original positive data drives sales for all—yet as my billing showed, promised price competition doesn’t always materialize in real-world charges.
Why Transparency Matters
You deserve to know: Is this approved for my exact cancer? Is this product going to help me? What are the real risks? How does it work? Searching DailyMed yourself reveals a lot.
My severe reaction matched the black box warning—validating my experience. Asking questions empowered me.
The Key Resource: NIH’s DailyMed Database
This free tool from the National Library of Medicine is a game-changer for patient advocacy. It gives you the official FDA-approved drug labeling—straight from the source, reformatted for easier reading.
Here’s how to use it step by step to dig into any prescribed medication:
Find the Exact Drug Name: Check the drug’s label or your medical billing statement (it’s often buried in the detailed codes—mine came from Mayo Clinic). Use the precise name, like “rituximab-pvvr (RUXIENCE)” or the NDC code if you have it, for the best match.
Search DailyMed: Go to the NIH DailyMed Database and enter the drug name (or NDC/active ingredient). Locate your specific medication/version.
Review Key Sections Yourself First:
Indications and Usage: Compare approved uses vs. your condition—is it on-label or off-label?
Warnings and Precautions: Look for black box warnings, serious risks, and infusion reactions (like mine).
Clinical Studies: Examine the trials behind approval. Note:
Do they include a placebo, or are they just comparing against similar drugs?
What’s the study size? (Rare disease trials are often small, limiting reliability.)
What are the trade-offs? (e.g., Is it worth long-term side effects for just 2 extra months of survival?)
What are the long-term side effects?
Take It Further with AI: Once you’ve found the right page, copy the full URL from your browser (it will look something like https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=…). Paste that exact link into an AI platform (like Grok, ChatGPT, or similar). Then ask your specific questions about that medication. This keeps the AI focused on the official details and helps you unpack complex sections—like interpreting study results, risks, or why certain data might not apply to your case.
Conclusion
Knowledge reduces fear and builds better decisions. Explore these tools, ask questions, share experiences (here or in communities). Wishing strength to everyone navigating this—may you find your path to wholeness too.
For the last three parts, we’ve traced how the Orphan Drug Act of 1983 started with genuine compassion, how the Rare Diseases Act of 2002 turned rare conditions into permanent federal infrastructure, and how the result is a trillion-dollar self-perpetuating industry that multiplies labels, inflates spending, and rewards management over cures. The system has no incentive to reduce disease prevalence, no requirement to prove fewer people need lifelong therapy, and no interest in exploring root causes when pharmaceutical control is more profitable.
What follows is real-world counter-evidence—one patient’s outcome that challenges the prevailing model. This is my story.
In late 2023, I was diagnosed with Primary CNS Lymphoma (PCNSL)—a “rare, aggressive, incurable” brain cancer. The standard protocol calls for high-dose methotrexate (HD-MTX), rituximab, temozolomide, and lifelong maintenance or repeated cycles of HD-MTX to keep this cancer from returning. If I was “lucky,” after 5-6 rounds, I’d qualify for an autologous stem cell transplant—harvesting my own cells to rebuild marrow destroyed by the chemo, all while the industry search for a “cure” drags on. A search first formalized in 1971 by Richard Nixon with the National Cancer Act, when he announced that if we can cure Hodgkin’s we can cure cancer.
At my doctor’s urging, I started HD-MTX just 10 days after landing in the ER—and a week after heavy antibiotics targeted what I believed was the real trigger: an active and chronic dental infection sparking my body’s lymphatic overreaction. While I was learning about the healthcare system and finding my way out, I went through four cycles of HD-MTX, and one dose each of rituximab and temozolomide.
By January 17, 2024, I’d gathered enough intel to plot my escape. Navigating my healthcare portal, I scrutinized my brain scans. What I saw didn’t scream “aggressive”—no rapid changes, just a body responding. It made more sense to challenge the story I was being told than to continue poisoning myself. I was learning in real time, unraveling rules and assumptions I wished I had known before the diagnosis. |
That day, admitted for what became my final cycle of HD-MTX, I refused anti-nausea meds. Vomiting, I argued, was my body’s natural defense against toxins—something it had done with cigarettes, alcohol, or even overwhelming experiences in my past. Why suppress that signal? Andrew Walker, the PA on shift, came in to talk. He listened thoughtfully as I shared my journey, my search for truth, and my question: Was it the antibiotics, the steroids or MTX driving any response? When he walked out that door, I expected to be shown the door—maybe even discharged from the program after he talked with the team.
Instead, he returned with “the Team” – Dr. Mrugala, Dr. Rosenthal, and others. The team couldn’t risk uncontrolled vomiting—I understood that. I told them plainly I believed my body could heal if I addressed the root cause. I said ” I am fearfully and wonderfully made.”
They listened, whether they heard me or were just nodding in agreement to get past this crisis. In my mind, I had just agreed to this last round, including anti-nausea for safety, on one condition: I’d head home to my octogenarian periodontist to tackle the infection. And that’s what I did. Looking back now, with everything I know, I would have left Mayo’s care on day 9—before ever starting chemotherapy. But fear and pressure kept me in longer than I should have stayed.
Fast-forward two years. My January 2026 MRI shows continued stability, with no new lesions and no meaningful progression of FLAIR hyperintensities. In the side-by-side comparison, the earlier scan (right) resembles a “lion’s face,” its mane formed by flaring abnormalities around the brain’s center. In the most recent image (left), those features appear subdued and organized—the central structures tamed, the brain moving from roaring to resting.
On January 19, 2026, I returned to my doctor, and we reviewed the imaging. We agreed that I would permanently step away from Mayo Clinic’s monitoring of my “disease.” There was no fanfare when I walked out—no longer their patient. No one is ringing my “I beat cancer” bell but me.
I am no longer living on borrowed time. I am living on healing on my terms—without endless toxicity.
The system is structured around features that are rarely disclosed to patients. These are the priorities and mechanisms I wish I had understood earlier:Drugs are prioritized over whole-body health. Medical care often follows rigid treatment playbooks that focus on pharmaceuticals, and once those regiments are established, they are rarely questioned or revisited.
Suppression replaces biological support. Rather than helping the body’s natural defense systems do their job, many treatments are designed to shut them down—most notably by targeting the lymphatic and immune systems first, even as they are actively working to protect and stabilize the body.
Approvals continue without ongoing proof. Once a drug is approved, it can remain in use indefinitely, even when long-term effectiveness is not regularly re-evaluated or meaningfully tracked.
Rules are bent for labels, not outcomes. Regulatory flexibility around “rare” disease classifications serve faster approvals and bureaucratic objectives rather than ensuring real, patient-centered results.
Important gaps are left uncovered. Insurance routinely excludes testing that could explain ongoing symptoms—such as evaluations for gadolinium toxicity—simply because those tests fall outside standard pathways.
Drugs gain freedom, patients do not. After approval for a single cancer indication, drugs can be reused broadly in small patient groups without rigorous endpoints, long-term follow-up, or meaningful outcome tracking.
Treatment rules are shaped by industry. Pharmaceutical companies develop the drugs, influence testing, and help shape hospital protocols—often through industry-entangled organizations like National Comprehensive Cancer Network—aligning care more closely with profit and stock performance than with patients’ long-term well-being.
Language is used to narrow choices. Fear-based terms like “aggressive,” “incurable,” and “unbeatable” are routinely used to frame disease, discouraging questions and implying patient helplessness rather than describing biological reality.
Patients are kept in a treatment loop. Most are never told that stopping, monitoring, or supporting the body is an option, ensuring continued enrollment in regiments that sustain dependency, funding streams, registries, and repeat interventions instead of resolution.
My message to anyone reading this series: You are not a disease label. Your body is remarkable. When the protocol feels like destruction, question it. Seek second opinions. Trust your intuition. Explore nutrition, detoxification, inflammation reduction, and lifestyle—the things the system sidelines because they can’t be patented or scaled. Healing is possible. Freedom is possible.
The industry we have created thrives on dependency. But individuals can break free—and when we do, we prove the whole narrative wrong.
The Orphan Drug Act of 1983 and the Rare Diseases Act of 2002 were intended to reduce suffering by accelerating cures for rare conditions.
After more than four decades and billions in public spending, rare diseases have not diminished. They have multiplied—while an already bloated government spending program continues to expand, with no indication of an endpoint.
This is what has happened:
The Growth in Identified Rare Diseases
From just over 6,000 recognized in 2002, the count now exceeds 10,000 (per NIH, NORD, and Orphanet estimates as of 2025–2026), with new subtypes and classifications added yearly through advances in genetics, molecular diagnostics, and data aggregation. This outcome is not accidental; it is a feature of the current model.
Year
Estimated Number of Rare Diseases Identified
2002
~6,000
2009
~5,850
2016
~6,080
2020
~7,000
2022
~10,000+
2026
~11,250+ (growing by ~250-300 annually)
More labels translate to more patients identified, more protocols developed, and more lifelong management—not fewer people suffering. The economic burden reflects the same pattern: Rare diseases cost the U.S. nearly $1 trillion annually. Trillions are being spent collectively, yet meaningful reductions in prevalence or treatment dependency remain elusive. The overwhelming majority of rare diseases still have no cure; only about 5% have FDA-approved treatments.
Government Spending by Agency (Billions USD)
The increase in identified diseases correlates directly with massive increases in public spending, particularly on healthcare coverage (Medicare/Medicaid) as opposed to core research (NIH).
Year
NIH (Research)
FDA (Grants)
Medicare/Medicaid (Treatment)
Total Approx.
2002
~$1.0B
$0.013B
Not Tracked
~$1.01B+
2009
$3.1B
$0.014B
~$3.0B
~$6.11B+
2016
$4.9B
$0.016B
$10.0B
~$14.92B+
2020
$6.0B
$0.016B
$18.5B
~$24.52B+
2022
$7.2B
$0.017B
$27.1B
~$34.32B+
2026
$4.4B (Est.)
$0.019B
$33.0B (Est.)
~$37.42B+
Activity vs. Progress
This outcome is by design. The system equates activity with progress: more grants awarded, more registries established, more approvals granted, more subtypes defined. Incentives reward participation and expansion—tax credits, market exclusivity, public-private collaborations—but impose no outcome-based accountability. There is no requirement to demonstrate fewer patients over time, fewer people needing lifelong therapy, or actual disease reduction. When prevalence rises or new diagnostic categories emerge, the funding continues unabated.
Regulatory flexibility, originally intended to address small patient populations, has granted pharmaceutical companies considerable leeway:
Smaller Trials: Often involving only dozens of participants rather than thousands.
Surrogate Endpoints: Using laboratory markers deemed “reasonably likely” to predict benefit, rather than direct evidence of clinical improvement like extended survival.
Accelerated Approvals: Allowing initial marketing based on weaker data while post-approval confirmatory studies are frequently delayed or remain incomplete.
What began as exceptional accommodation has become routine, lowering evidentiary thresholds and enabling more drugs to reach the market with limited proof of resolving the underlying disease.
The Transparency Gap and Sidelined Interventions
Patients frequently receive incomplete information. While physicians must obtain informed consent, no federal rule mandates explicit disclosure that a drug is being used off-label, that supporting evidence derives from small trials or surrogate markers, or that long-term benefits and risks remain uncertain. This transparency gap places the full burden of uncertainty and potential harm squarely on the patient.
Non-patentable interventions—chronic infections, inflammatory drivers, environmental exposures, nutritional optimization, metabolic repair—are systematically sidelined. They lack the exclusivity or high-margin potential needed to attract large-scale funding or study. The system overwhelmingly favors scalable, reimbursable pharmaceutical solutions over investigation of root causes.
The human toll is profound and unforgivable. Patients endure aggressive, body-destroying regimens while underlying triggers go unexplored. They are told their disease is aggressive, rare, and incurable, then funneled into protocols designed for control rather than resolution.
What we really have created is a massive, well-funded, self-perpetuating industry: government-business partnerships, advocacy ecosystems, and lifelong treatment protocols—all thriving on more recognized diseases, more spending, and more dependency. Not progress. Institutionalized failure.
The next part begins at the moment a patient realizes they are not being guided toward recovery but managed as an endpoint in a system with no incentive to make them well—and decides to leave it.
Part 1 examined how the Orphan Drug Act of 1983 used incentives to correct a market failure—and why it worked. But that law was never intended to create a permanent system.
In 2002, that changed. With the Rare Diseases Act, rare diseases stopped being an exception to the medical marketplace and became embedded in the federal research infrastructure itself. This essay examines how a temporary solution quietly sowed the seeds for something much larger, with consequences that were not anticipated at the time.
The Orphan Drug Act of 1983 has proven its value. By offering tax credits, grants, and seven years of market exclusivity, it spurred hundreds of orphan drug designations and approvals where none had existed before. What was once a neglected corner of medicine began to attract real investment. But the law’s incentives were narrowly focused on drug development—temporary bridges over a market gap. Rare diseases were addressed as exceptions, not yet embedded as a standing priority within the medical system.
In 2002, Congress took the next step. On November 6, President George W. Bush signed the Rare Diseases Act into law. Unlike the Orphan Drug Act, which relied on pharmaceutical incentives, this legislation embedded rare diseases directly into the federal research infrastructure at the National Institutes of Health (NIH).
The Act’s congressional findings captured the scale of the problem at the time: more than 6,000 known rare diseases affecting an estimated 25 million Americans, many of whom lacked effective treatments due to limited commercial interest. The law sought to address this by formalizing rare disease research through several key mechanisms:
Establishing a statutory Office of Rare Diseases—now the Office of Rare Diseases Research (ORDR) within the National Center for Advancing Translational Sciences—to coordinate NIH efforts
Recommending a national research agenda for rare diseases
Supporting education, workshops, and symposia to identify research opportunities
Authorizing grants for regional centers of excellence, which led to the creation of the Rare Diseases Clinical Research Network (RDCRN) to support collaborative clinical studies, training, and patient engagement
The Act also standardized the definition of a rare disease as any condition affecting fewer than 200,000 people in the United States—the same threshold used in the Orphan Drug Act—and authorized modest appropriations (approximately $4 million annually from FY 2003–2006). Though limited in dollar terms, this funding signaled a long-term federal commitment.
The shift was profound. Rare diseases were no longer addressed solely through targeted incentives; they became a formalized category within federal medicine, complete with dedicated offices, recurring grant pipelines, disease registries, and collaborative frameworks linking government, academia, industry, and advocacy organizations. Across this ecosystem, sustained participation—not resolution—was rewarded.
Since 2002, this infrastructure has driven substantial investment. Federal funding coordinated through ORDR, RDCRN cycles, and related NIH grants is estimated at $2–4 billion, with RDCRN alone exceeding $500–600 million across its five funding cycles. The system expanded research capacity, built networks, and increased visibility for rare conditions. But the numbers also reveal a deeper paradox. While the 2002 Act referenced roughly 6,000 known rare diseases, the recognized total has since climbed well beyond 10,000. This increase is often attributed to advances in genetics, molecular diagnostics, and data aggregation—suggesting that many conditions always existed but were previously unidentified. Yet that explanation is incomplete.
Over the same period, Americans have experienced unprecedented and cumulative exposure to thousands of synthetic chemicals, food additives, pharmaceuticals, and environmental contaminants—many approved under fragmented regulatory oversight and rarely studied for long-term, low-dose, or synergistic effects. Rather than asking whether this expanding chemical burden is contributing to disease emergence, the system has largely focused on classification and management after the fact. More diseases are cataloged, more subtypes defined, and more patients enrolled—not necessarily because detection has improved alone, but because upstream causes remain unaddressed.
Rare disease was now a permanent federal program to manage, not a temporary gap to close. No built-in mechanisms required measuring reductions in disease prevalence, cures achieved, or fewer patients needing lifelong care. Success became increasingly tied to activity—more studies, more centers, more funding—rather than to resolution.
What began as compassion had evolved into something enduring: a formal system with billions invested, expanding infrastructure, and a growing catalog of recognized diseases. After more than four decades, what has that investment actually produced?
When Compassion Met Incentives: The Orphan Drug Act of 1983 (Part 1 of 4)
In the late 1970s and early 1980s, families across America watched helplessly as loved ones died from rare diseases—conditions so uncommon that pharmaceutical companies saw little profit in developing treatments. Doctors had few options. Researchers had limited funding. Patients had no real leverage. These “orphan” diseases affected small populations, often fewer than 200,000 Americans, making them unappealing to market-driven drug development.
Congress responded with bipartisan urgency. On January 4, 1983, President Ronald Reagan signed the Orphan Drug Act (ODA) into law, amending the Federal Food, Drug, and Cosmetic Act to encourage the creation of drugs for rare diseases.
The core idea was simple and humane: If private industry wouldn’t invest because the patient pool was too small to recoup costs, the government would make it worthwhile through targeted incentives. Those incentives were designed to reduce risk, shorten timelines, and make rare disease research economically viable.
Key provisions included:
Orphan drug designation: Companies could apply to the FDA for a drug to be designated as an “orphan” if it targeted a rare disease (defined as affecting < 200,000 people in the U.S., or more if no reasonable expectation of profitability). This unlocked benefits early in development.
Tax credits: Up to 50% of qualified clinical trial costs could be claimed as a credit, reducing the financial burden of research.
Market exclusivity: Upon FDA approval, the first sponsor received seven years of exclusive marketing rights for that drug in treating the designated rare condition—no direct competitors could enter the market during that period.
Grant funding: The FDA’s Office of Orphan Products Development awarded research grants to support orphan drug studies.
Fee waivers: Exemption from Prescription Drug User Fee Act (PDUFA) application fees.
Regulatory support: Priority review, closer FDA coordination, and access to expedited pathways.
These carrots worked. Before 1983, the FDA had approved only about 10 drugs that would qualify as orphans. In the decades since, hundreds of orphan designations have led to over 500 approvals for rare disease treatments, transforming what was once a neglected area into one of sustained innovation.
At its heart, the 1983 Act was an act of compassion translated into policy—bridging a market failure to give hope to patients long ignored. It proved that targeted government intervention could spur private investment where pure economics had failed.
Yet this success planted seeds for what came next: a system that, over time, grew far beyond its original intent.
What began as a targeted solution to a market failure would not remain temporary. In the years that followed, rare disease moved from exception to infrastructure—embedded into federal research, funding, and regulation.
Linda Wulf is a cancer rebel, advocate, and independent researcher. Diagnosed in 2023 with primary CNS lymphoma, she declined standard chemotherapy and pursued a root-cause, immune-supporting path. Twenty-three months cancer-free via root-cause approach.
That means that by the early 1990s, roughly nine out of ten Americans receiving artificially fluoridated municipal water were served by systems using fluorosilicate chemicals rather than sodium fluoride.
